TREATMENT OF PATIENTS WITH SMALL CELL LUNG CANCER

A.在海军海军医院接受治疗的小细胞肺癌患者 内科肿瘤科和退伍军人肿瘤科 没有患癌症的时间越长，罹患癌症的风险就会增加16倍。 第二例原发非小细胞肺癌与普通 人口。发展为第二个原发非小细胞肺的风险 在43名戒烟患者中，癌症增加了11倍 12名患者罹患小细胞肺癌的比例为32倍 继续吸烟的人。戒烟成功后戒烟成功 治疗与降低罹患第二胎的风险有关 与吸烟相关的原发癌症。 B.451例非霍奇金淋巴瘤患者的分期调查信息 之前未经治疗的小细胞肺癌进入NCI的研究- 收集了海军肿瘤科和退伍军人管理局。 对每个分期过程的成本进行了估计，并提出了一个算法 被构造为分析过程序列的所有排列 需要对小细胞肺癌患者进行疾病分期。这个 最便宜的程序可能会节省1,418.00美元 与对所有患者执行所有分期程序进行比较。 降低成本的主要因素是停止试运行的概念 在确定远处转移性疾病的部位后进行手术。

A. The patients with small cell lung cancer treated at the NCI-Navy Medical Oncology Branch and VA Oncology Branch who survived for two or more years free of cancer were at a 16-fold increased risk of developing a second primary non-small cell lung cancer compared to the general population. The risk of developing a second primary non-small cell lung cancer was 11-fold increased in the 43 patients who stopped smoking after developing small cell lung cancer compared to 32-fold in the 12 patients who continued to smoke. Cigarette smoking cessation after successful therapy is associated with a decrease in risk of developing a second smoking-related primary cancer. B. The information on staging investigations of 451 patients with previously untreated small cell lung cancer entered onto study at the NCI- Navy Medical Oncology Branch and Veterans Administration was collected. The cost of each staging procedure was estimated and an algorithm was constructed analyzing all permutations of a sequence of procedures required to stage disease in patients with small cell lung cancer. The least expensive sequence of procedures could potentially save $1,418.00 per patient compared to performing all staging procedures on all patients. The major factor in reducing costs was the concept of stopping the staging procedures after a site of distant metastatic disease was identified.